RICHTER GEDEON SHARERR

RICHTER GEDEON SHARE

10,200HUFD
+110+1.09%
At close at Jun 6, 15:11 GMT
HUF
No trades
See on Supercharts

RICHTER fundamentals

Key facts

Market capitalization‪1.87 T‬HUF
Basic EPS (TTM)1,308.53HUF
Founded1901
Employees (FY)‪11.76 K‬
CEOGábor Orbán
Websiterichter.hu
About

Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

Ownership
‪‪182.85 M‬‬
Free Float shares
‪‪133.16 M‬‬ (72.82%)
Closely held shares
‪‪49.70 M‬‬ (27.18%)
Free Float shares
‪‪133.16 M‬‬ (72.82%)
Closely held shares
‪‪49.70 M‬‬ (27.18%)
Capital structure
Market cap
‪‪1.87 T‬‬
Debt
‪‪21.33 B‬‬
Minority interest
‪‪3.22 B‬‬
Cash & equivalents
‪‪201.78 B‬‬
Enterprise value
‪‪1.69 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.87 T‬‬
Price to earning ratio (P/E)
7.71x
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
7.71x
Price to sales ratio (P/S)
Valuation ratios
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪2.50‬
‪5.00‬
‪7.50‬
‪10.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪15%‬
‪20%‬
‪25%‬
‪30%‬
‪35%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
‪‪240.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
‪‪240.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
‪‪240.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Women's Healthcare
General Medicines
Neuropsychiatry
Biotechnology
Other
Pharma Other
By country
Period: 2024
United States
Other
Europe
Russia
Hungary
Poland
Germany
Spain
China
Latin America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
‪‪240.00 B‬‬
Actual
Estimate
Earnings
Next:Aug 6, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪100.00‬
‪200.00‬
‪300.00‬
‪400.00‬
Actual

Dividends

Dividend yield, history and sustainability

Dividend summary
38.90%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
4.28%
Last payment
509.00
Last ex-date
Jun 3, 2025
Last pay date
Jun 12, 2025
Dividend history
‪2.5%‬
‪3.2%‬
‪3.9%‬
‪4.6%‬
‪5.3%‬
2020
2021
2022
2023
2024
‪0.00‬
‪130.00‬
‪260.00‬
‪390.00‬
‪520.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪55.00 B‬‬
‪‪110.00 B‬‬
‪‪165.00 B‬‬
‪‪220.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪250.00 B‬‬
‪‪500.00 B‬‬
‪‪750.00 B‬‬
‪‪1.00 T‬‬
Assets
Liabilities